| Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts TK Karikari, TA Pascoal, NJ Ashton, S Janelidze, AL Benedet, ... The Lancet Neurology 19 (5), 422-433, 2020 | 892 | 2020 |
| Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology NJ Ashton, TA Pascoal, TK Karikari, AL Benedet, J Lantero-Rodriguez, ... Acta neuropathologica 141, 709-724, 2021 | 398 | 2021 |
| Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 N Kanberg, NJ Ashton, LM Andersson, A Yilmaz, M Lindh, S Nilsson, ... Neurology 95 (12), e1754-e1759, 2020 | 392 | 2020 |
| Microglial activation and tau propagate jointly across Braak stages TA Pascoal, AL Benedet, NJ Ashton, MS Kang, J Therriault, M Chamoun, ... Nature medicine 27 (9), 1592-1599, 2021 | 308 | 2021 |
| Steroid‐responsive encephalitis in coronavirus disease 2019 A Pilotto, S Odolini, S Masciocchi, A Comelli, I Volonghi, S Gazzina, ... Annals of neurology 88 (2), 423-427, 2020 | 303 | 2020 |
| A multicentre validation study of the diagnostic value of plasma neurofilament light NJ Ashton, S Janelidze, A Al Khleifat, A Leuzy, EL van der Ende, ... Nature communications 12 (1), 3400, 2021 | 297 | 2021 |
| Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease JB Pereira, S Janelidze, R Smith, N Mattsson-Carlgren, S Palmqvist, ... Brain 144 (11), 3505-3516, 2021 | 268 | 2021 |
| Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline J Lantero Rodriguez, TK Karikari, M Suárez-Calvet, C Troakes, A King, ... Acta neuropathologica 140, 267-278, 2020 | 260 | 2020 |
| Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ... JAMA neurology 78 (12), 1471-1483, 2021 | 259 | 2021 |
| Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ … M Suárez‐Calvet, TK Karikari, NJ Ashton, J Lantero Rodriguez, ... EMBO molecular medicine 12 (12), e12921, 2020 | 255 | 2020 |
| Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative TK Karikari, AL Benedet, NJ Ashton, J Lantero Rodriguez, A Snellman, ... Molecular psychiatry 26 (2), 429-442, 2021 | 245 | 2021 |
| Plasma proteins predict conversion to dementia from prodromal disease A Hye, J Riddoch-Contreras, AL Baird, NJ Ashton, C Bazenet, R Leung, ... Alzheimer's & Dementia 10 (6), 799-807. e2, 2014 | 244 | 2014 |
| The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease J Simrén, A Leuzy, TK Karikari, A Hye, AL Benedet, J Lantero‐Rodriguez, ... Alzheimer's & Dementia 17 (7), 1145-1156, 2021 | 217 | 2021 |
| Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease M Milà-Alomà, NJ Ashton, M Shekari, G Salvadó, P Ortiz-Romero, ... Nature Medicine 28 (9), 1797-1801, 2022 | 210 | 2022 |
| Biomarkers for tau pathology M Schöll, A Maass, N Mattsson, NJ Ashton, K Blennow, H Zetterberg, ... Molecular and Cellular Neuroscience 97, 18-33, 2019 | 209 | 2019 |
| Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease A Moscoso, MJ Grothe, NJ Ashton, TK Karikari, JL Rodríguez, A Snellman, ... JAMA neurology 78 (4), 396-406, 2021 | 188 | 2021 |
| Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum A Moscoso, MJ Grothe, NJ Ashton, TK Karikari, JL Rodriguez, A Snellman, ... Brain 144 (1), 325-339, 2021 | 170 | 2021 |
| Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease S Janelidze, D Bali, NJ Ashton, NR Barthélemy, J Vanbrabant, E Stoops, ... Brain 146 (4), 1592-1601, 2023 | 168 | 2023 |
| Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring NJ Ashton, S Janelidze, N Mattsson-Carlgren, AP Binette, O Strandberg, ... Nature medicine 28 (12), 2555-2562, 2022 | 164 | 2022 |
| An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders NJ Ashton, A Hye, AP Rajkumar, A Leuzy, S Snowden, M Suárez-Calvet, ... Nature Reviews Neurology 16 (5), 265-284, 2020 | 159 | 2020 |
Henrik ZetterbergSahlgrenska在 clinchem.gu.se 的电子邮件经过验证
